ClinicalTrials.gg
Active, not recruitingNCT04765657Updated Dec 30, 2025

Study of Efficacy and Safety of Inclisiran in Asian Participants With Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD High Risk and Elevated Low Density Lipoprotein Cholesterol (LDL-C)

A Phase 3 interventional study of inclisiran sodium and Placebo in Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 45 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
345
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.

Enrollment
14th of 24
345 · median 375
Started
2021
with 4 others
Phase 3
13 of 24
2 open now
Registered
8th of 24
by date
Lead sponsor
16 of 24
Novartis Pharmaceuticals

Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 14th largest by enrollment, is one of 5 that started in 2021, is one of 13 in phase 3, and was the 8th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About inclisiran

inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing inclisiran in Hypercholesterolemia, or all of them as a file.
02

Study summary

A multicenter study to evaluate safety and efficacy of inclisiran in Asian patients with ASCVD or ASCVD high risk and elevated LDL-C

Read the detailed description

The purpose of the study is to demonstrate the efficacy and safety of inclisiran sodium 300mg to support the indication for LDL-C reduction of inclisiran in Asian patients with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-high risk patients with elevated LDL-C as an adjunct to diet and maximally tolerated dose statins with or without additional lipid-lowering therapy.

A core part (2-week screening period and a 12-month double-blinded treatment period), and an extension part (until reasonable access to the IMP post product launch provided for the participants)

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • inclisiran
  • siRNA
  • dyslipidemia
  • KJX839
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-At screening participants with: ASCVD (including acute coronary syndrome (ACS), stable coronary heart disease, post revascularization, ischemic cardiomyopathy, ischemic stroke, (TIA), and peripheral atherosclerosis) and Serum LDL-C ≥1.8 mmol/L (≥70 mg/dL) OR ASCVD high risk (LDL-C ≥4.9 mmol/L, diabetes, high 10-year ASCVD risk assessed by Chinese ASCVD Risk Assessment Flow Chart , or high risk per local guidelines with a target LDL-C of \<100 mg/dL) and Serum LDL-C ≥2.6 mmol/L (≥100 mg/dL)

  • Fasting triglyceride \< 400 mg/dL (\< 4.52 mmol/L) at screening.
  • Participants on statins should be receiving a maximally tolerated dose . Maximum tolerated dose is defined as the maximum dose of statin that can be taken on a regular basis without intolerable AE. Intolerance to any dose of statin must be documented as historical AEs attributed to the statin in question on the source documentation and on the Medical history page of the eCRF
  • Participants not receiving statin must have a documented evidence of intolerance to all doses of at least 2 different statins(or the corresponding local definition of complete intolerance to statins)
  • Participants following lifestyle modification should be on the therapy of LDL-C lowering (such as statin monotherapy, or statin incombination with ezetimibe) with a stable dose for ≥30 days before screening and have no planned medication or dose change during study participation.
  • Participants are willing and able to give before initiation of any study related procedures and willing to comply with all required study procedures.

Exclusion criteria

Exclusion Criteria:

  • (NYHA) class IV heart failure or last known \<25%.
  • Cardiac arrhythmia with clinical significance within 3 months prior to randomization that is not controlled by medication or via ablation.
  • Major adverse cardiovascular event within 3 months prior to randomization.
  • Uncontrolled severe hypertension: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg prior to randomization despite antihypertensive therapy.
  • Calculated ≤30 mL/min by estimated glomerular filtration rate (eGFR) using standardized clinical methodology.
  • Severe concomitant non-cardiovascular disease that carries the risk of reducing to less than 2 years.
  • History of that required surgery (excluding local and wide-local excision), radiation therapy and/or systemic therapy during the three years prior to randomization.
  • Barrier method: Condom or Occlusive cap (e.g. diaphragm or cervical/vault caps).
  • Other protocol-defined inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
345 participants (actual)

Study arms

  • Experimental
    inclisiran sodium 300 mg

    Subcutaneous injection

    Drug: inclisiran sodium

  • Placebo comparator
    Placebo

    Subcutaneous injection

    Drug: Placebo

Interventions

  • Subcutaneously injected on Day 1, 90 and 270 (Core Part). Subcutaneously injected on Day 360 and every 6 months thereafter until EOS visit (Extension Part)

    Also known as: KJX839

  • DrugPlacebo

    Subcutaneously injected on Day 1, 90, and 270.

06

What researchers measure

Primary outcomes

  1. Core: Percentage change in low- density lipoprotein cholesterol (LDL-C)

    Superiority of inclisiran compared to placebo in reducing LDL-C from baseline to Day 330

    Time frame: Baseline, Day 330

  2. Extension: Number of participants with Adverse Events

    Evaluation of the safety and tolerability of inclisiran, treatment emergent Adverse events and Serious Adverse Events

    Time frame: Day 360 until study completion, an average of 3 years

Secondary outcomes

  1. Core: Time adjusted percentage change in LDL-C

    The superiority of inclisiran compared to placebo in reducing LDL-C from baseline to Day 330 and over time

    Time frame: From baseline after Day 90 and up to Day 360

  2. Core: Absolute change in LDL-C

    The superiority of inclisiran compared to placebo in reducing LDL-C from baseline to Day 330 and over time

    Time frame: From baseline to Day 330

  3. Core: Time adjusted absolute change in LDL-C

    The superiority of inclisiran compared to placebo in reducing LDL-C from baseline to Day 330 and over time

    Time frame: From baseline after Day 90 and up to Day 360

  4. Core: Percentage change in PCSK9

    The superiority of inclisiran compared to placebo in reducing PCSK9 from baseline to Day 330

    Time frame: From baseline to Day 330

  5. Core: Absolute change in PCSK9

    The superiority of inclisiran compared to placebo in reducing PCSK9 from baseline to Day 330

    Time frame: From baseline to Day 330

  6. Core: Proportion of participants reaching LDL-C levels of <25 mg/dL, <50 mg/dL, <70 mg/dL, and <100 mg/dL

    The superiority of inclisiran compared to placebo in individual response rate for lipid controlling

    Time frame: Day 330

  7. Core: Proportion of participants in each group with ≥ 50% LDL-C reduction

    The superiority of inclisiran compared to placebo in individual response rate for lipid controlling

    Time frame: From baseline to Day 330

  8. Core: Proportion of participants in each group who attain global lipid targets for their level of ASCVD risk (55mg/dl for ASCVD patients, 70mg/dl for ASCVD high risk patients)

    The superiority of inclisiran compared to placebo in individual response rate for lipid controlling

    Time frame: Day 330

  9. Core: Percentage change in total cholesterol, ApoB, non-HDL-C, ApoA1, HDL-C, Lp(a) and triglycerides

    The superiority of inclisiran compared to placebo in reducing other lipids, lipoproteins and apolipoproteins

    Time frame: From baseline to Day 330

  10. Core: Absolute change in total cholesterol, ApoB, non-HDL-C, ApoA1, HDL-C, Lp(a) and triglycerides

    The superiority of inclisiran compared to placebo in reducing other lipids, lipoproteins and apolipoproteins

    Time frame: From baseline to Day 330

07

Study locations

45 sites
  • Novartis Investigative Site
    Lanzhou, Gansu 730030, China
  • Novartis Investigative Site
    Foshan, Guangdong 528000, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
  • Novartis Investigative Site
    Shijiazhuang, Hebei 050000, China
  • Novartis Investigative Site
    Baotou, Inner Mongolia 014040, China
  • Novartis Investigative Site
    Hohhot, Inner Mongolia 010017, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210008, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 211166, China
  • Novartis Investigative Site
    Nantong, Jiangsu 226000, China
  • Novartis Investigative Site
    Suzhou, Jiangsu 215004, China
  • Novartis Investigative Site
    Xuzhou, Jiangsu 221003, China
  • Novartis Investigative Site
    Changchun, Jilin 130000, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Jinan, Shandong 250013, China
  • Novartis Investigative Site
    Jinshan, Shanghai Municipality 201508, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030002, China
  • Novartis Investigative Site
    Xian, Shanxi 710061, China
  • Novartis Investigative Site
    Tianjin, Tianjin Municipality 300121, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310014, China
  • Novartis Investigative Site
    Beijing, 100034, China
  • Novartis Investigative Site
    Beijing, 100039, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Beijing, 100191, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Shanghai, 200040, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Shanghai, 200120, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Tianjin, 300140, China
  • Novartis Investigative Site
    Xiamen, 361004, China
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 169609, Singapore
  • Novartis Investigative Site
    Wŏnju, Gangwon-do 26427, South Korea
  • Novartis Investigative Site
    Incheon, Korea 405 760, South Korea
  • Novartis Investigative Site
    Seoul, Korea 02841, South Korea
  • Novartis Investigative Site
    Seoul, Korea 03080, South Korea
  • Novartis Investigative Site
    Seoul, Seoul 06351, South Korea
  • Novartis Investigative Site
    Seoul, South Korea 110-746, South Korea
  • Novartis Investigative Site
    Gwangju, 61469, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Seoul, 05505, South Korea
  • Novartis Investigative Site
    Kaohsiung City, 80756, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
  • Novartis Investigative Site
    Taipei, 11220, Taiwan
08

References and documents

Publications

  • Huo Y, Lesogor A, Lee CW, Chiang CE, Mena-Madrazo J, Poh KK, Jeong MH, Maheux P, Zhang M, Wei S, Han Y, Li Y. Efficacy and Safety of Inclisiran in Asian Patients: Results From ORION-18. JACC Asia. 2023 Nov 14;4(2):123-134. doi: 10.1016/j.jacasi.2023.09.006. eCollection 2024 Feb. PubMed 38371290 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jun 2022, 15 months.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Feb 21, 2021
StartActual
Mar 1, 2021
Primary completionActual
Jun 9, 2022
CompletionEst.
Dec 28, 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04765657
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Mar 1, 2021
Primary completion
Jun 9, 2022
Completion
Dec 28, 2026 (estimated)
Last update
Dec 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion